Inclusion
- Signed written Informed Consent
- Age > 18 years
- Eastern Cooperative Oncology Group (ECOG) score 0 - 1.
- Histologically or cytologically confirmed colorectal cancer patients who have failed at least 2 lines of chemotherapy (monotherapy treatment cohorts) or at least 1 line of chemotherapy (combination treatment cohorts) for metastatic disease, and in the opinion of both physician and patient it is not unreasonable to try experimental therapy. Adjuvant FOLFOX within the last 6 months is considered a line of therapy. A maintenance strategy post 1st line treatment is not considered as an additional line of therapy.
- Patients must have accessible tumor lesions amenable to biopsy which would not put the patient or their treatment at risk. Patients in monotherapy escalation cohort 3 and onwards, the monotherapy expansion cohort, and all combination treatment patients, agree and are willing to provide 2 serial tumor lesion biopsies (a minimum of 2 fresh cores/punches preferred whenever possible). Biopsies can be from liver metastases, in lieu of the primary tumor. The presence of tumor tissue in fresh biopsies is to be certified by a trained pathologist using appropriate extemporaneous histology or cytology procedures. Refer to Appendix 6 for biopsy procedures.
- All AEs of any prior chemotherapy, surgery, or radiotherapy, must have resolved to Grade ≤ 1.
- Measurable or evaluable disease per RECIST version 1.1.
- No known brain metastases (see also exclusion criterion No. 10).
- Life expectancy of at least > 12 weeks.
-
Normal organ and marrow function:
- Absolute neutrophil count (ANC) > 1,500/mL without growth factor support in the past 14 days prior to enrolment
- Platelets > 100,000/mL without transfusions in the past 14 days prior to enrolment
- Hemoglobin > 9.0 g/dL - Patients may be transfused or receive erythropoietic treatment to meet this criterion
- Total bilirubin < 1.5 x institutional upper limit of normal (ULN) (< 2 x ULN for subjects with Gilbert's syndrome)
- Serum albumin ≥ 3 g/dL.
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase, SGOT) and alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase, SGPT) < 2.5 x institutional ULN (for subjects with hepatic involvement < 5 x institutional ULN but cannot be associated with elevated bilirubin).
- Alkaline phosphatase (AlkPhos) > 2.5 x ULN, except in patients with documented liver or bone metastases, where it can be < 5 x ULN.
- For patients receiving biopsies, prothrombin time (PT) and activated partial thromboplastin time (APTT)/international normalized ratio (INR) within normal limits (± 15%)..
- Creatinine < 1.5 x institutional ULN OR Creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal based on the Cockroft-Gault glomerular filtration rate estimation:
(140 - age) x (weight in kg) x (0.85 if female)
72 x (serum creatinine in mg/dL)
(NOTE: For patients with a Body Mass Index (BMI) > 30 kg/m2, lean body weight should be used instead)
15. No clinically significant abnormalities in urinalysis results (obtained ≤ 14 days prior to enrolment).
16. No current or recent (within 3 months of study drug administration) gastrointestinal disease such as chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease. Non-chronic conditions (e.g., infectious diarrhea) that are completely resolved for at least 2 weeks prior to starting study treatment is allowed.
17. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form of contraception (e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for 6 months after the last dose of study drugs.
18. Women of childbearing potential must have a negative serum pregnancy test (β-hCG) within 72 hours prior to first study drug administration.